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Abstract
Paragangliomas and pheochromocytoma (PPGLs) are hereditary tumors in 
about 40% of cases. Mutations in the genes encoding for components of the mito-
chondrial succinate dehydrogenase protein complex (SDHB, SDHD, SDHC) are 
among the most prevalent. Most PPGLs have a benign behavior, but patients with 
germline SDHB mutations may develop metastatic PPGLs in up to 30% of cases. 
This suggest that the SDH substrate, succinate, is key for the activation of the 
metastatic cascade. The last decade has witnessed significant advances in our under-
standing of how succinate may have oncogenic properties. It is now widely accepted 
that succinate is an oncometabolite that modifies the epigenetic landscape of SDH-
deficient tumors via modulating the activities of DNA and histone modification 
enzymes. In this chapter, we summarize recent discoveries linking SDH-deficiency 
and metastasis in SDH-deficient PPGLs via inhibition of DNA methylcytosine 
dioxygenases, histone demethylases and modified expression of non-coding RNAs. 
We also highlight promising therapeutic avenues that may be used to counteract 
epigenetic deregulations.
Keywords: paraganglioma, pheochromocytoma, metastasis, epigenetic,  
DNA methylation, histone methylation, succinate
1. Introduction
Paragangliomas and pheochromocytomas (PPGLs) are rare neuroendocrine 
tumors that originate in the diffuse paraganglionic tissue and the adrenal gland, 
respectively. Approximately 40% of these tumors are hereditary and related to 
germline mutations in SDHB, SDHC, SDHA, SDHD and SDHAF2 (collectively 
called SDHx), as well as RET, VHL, NF1, TMEM127, MAX, FH, KIF1B and EGLN1 
among others [1]. Mutations in genes encoding different subunits of the succinate 
dehydrogenase (SDH) complex are the most prevalent in hereditary PPGLs being 
present in about 50% of cases. Among these genes, SDHB, SDHD and SDHC are 
the most frequently affected. Somatic mutations affecting SDHx genes can be 
also detected in non-hereditary PPGLs [2]. The strong association of SDHx muta-
tions and PPGLs reveals that the activity of this mitochondrial complex plays an 
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essential, and likely unique, role in the neuroendocrine tissues conforming human 
paraganglia such that its deregulation cause development of neoplasia in these tis-
sues that can, eventually, become metastatic.
One of the peculiarities of PPGLs is that they are generally slow growing, 
indolent tumors that are not life-threatening. However, 10–30% (according to 
different studies) of the PPGLs metastasize and once metastasis occurs, treatment 
options are rather limited and patients have poor prognosis, often with less than 
50% surviving at 5 years [3]. Surgery can improve the prognosis but standard 
chemotherapeutic regimen with cyclophosphamide, vincristine, and dacarbazine, 
or radionuclide therapy with 131 Iodine-radiolabelled metaiodobenzylguanidine 
result in only partial responses. Thus, there is still a long road to reach therapeutic 
improvements. Further challenges for clinicians come from the fact that, in half 
of the cases, metastases are not present during the initial treatment of the patient 
but emerge over a period of undetermined time, which may even exceed 10 years 
after diagnosis of the primary tumor. For this reason, these patients receive long-
term, post-treatment surveillance. However, the duration as well as the interval of 
the follow-up screening is poorly defined. Following these reasonings, the WHO 
2017 Classification of Tumors of Endocrine Organs stated that PPGLs should be 
considered as tumors of undetermined biologic potential and should not be termed 
benign but should be classified as metastatic or not metastatic [4]. Given that all 
PPGLs are recognized as exhibiting malignant potential to some extent, the risk for 
malignant behavior must be determined to be able to pinpoint cases at risk of future 
metastases directly in the early post-operative period, a knowledge that would have 
a significant clinical impact.
Despite overwhelming advances in understanding the molecular mechanisms 
of PPGL development made in the last decade, the factors governing the emergence 
of metastasis are still very poorly understood. Considerable efforts have been 
made in identifying histopathological features suggestive of metastatic behavior 
using pre-defined algorithms. The Pheochromocytoma of the Adrenal Gland 
Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and 
Paraganglioma (GAPP), rely on different histopathologic features or on a combina-
tion of histopathologic, immunohistochemical (Ki-67 index) and biochemical 
(catecholamine production) parameters, respectively, as tools to distinguish PPGLs 
with potential for aggressive behavior [5]. However, these algorithms lack accuracy 
and have a high degree of inter-observer variability thus complicating their clinical 
roll-out. Hence, the guiding of therapeutic decision-making by using predictive 
biomarkers in PPGL patients require in-depth knowledge of the biology of this 
neoplasia.
2.  Epigenetic and SDH-deficiency: a connection with metastatic 
potential
The metastatic cascade involves a succession of cell phenotypic alterations that 
spans from the acquisition of local invasive activity, the intravasation of cancer cells 
into blood and lymphatic vessels, their subsequent extravasation in the parenchyma 
of distant tissues and finally their growth forming macroscopic tumors. How a 
primary PPGL-tumor cell becomes metastatic and what are the molecular events 
involved in this process remain to be known. With the emergence of genomic 
profiling technologies, single gene/protein or multi-gene “signature”-based assays 
have been introduced to measure specific molecular pathway deregulations in 
cancer which could be used as clinically useful biomarkers. In PPGLs’ patients, 
it is well established that the presence of inactivating germline mutations in the 
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SDHB gene is the most important molecular predictor of malignancy. More than 
40% of patients with metastatic PPGLs (especially extra-adrenal tumors) carry 
germline SDHB mutations [6, 7]. Although mutations in other PPGL-predisposing 
genes, such as FH, SDHC, SDHD, SDHA, and TMEM127 have been found in some 
patients with metastatic PPGLs, these mutations account for only <5% of cases. The 
mitochondrial 2-oxoglutarate/malate carrier SLC25A11 gene has been proposed as a 
novel gene that can confer a predisposition to metastatic PPGLs but the number of 
patients harboring SLC25A11-germline mutations was rather limited to definitely 
assigned it a role in metastasis development [8]. Thus, SDHB gene germline muta-
tion remains as the most reliable risk factor for metastasis. Nonetheless, metastases 
are developed in only 30% of the SDHB-mutation carriers and it is not known what 
are the mechanisms that either tip the balance towards the metastatic process or 
prevent it in these patients. Recent studies have pointed to several cancer-related 
genetic deregulations in metastatic PPGLs, especially prevalent in SDHB-related 
tumors. These include activation of telomerase and over-expression of genes 
involved in epithelial to mesenchymal transition [9–11]. However, these molecular 
alterations have been found in limited number of metastatic PPGLs and it is not 
known what their role is as triggers of the metastatic process. Aside SDHB-related 
metastatic PPGLs, the specific genetic traits involved in the development of the 
remaining 60% of metastatic PPGLs are not known. Somatic mutations in ATRX 
and SETD2 genes, and fusions of MAML3 gene have been identified in metastatic 
PPGLs [12, 13].
One of the most relevant hints on the molecular mechanisms involved in 
metastasis came from the The Cancer Genome Atlas (TCGA) Program. These 
studies revealed that metastatic SDHx-mutated PPGLs do not accumulate more 
gene mutations at the somatic level than no-metastatic PPGLs [13]. It is now 
becoming increasingly evident that epigenetic changes play a key role in provid-
ing properties to the primary cancer cell that have a major contribution to the 
metastatic process. Relevant studies revealed that PPGLs, developed in patients 
with mutations in SDHx genes, harbor a DNA hypermethylation phenotype which 
is not present in PPGLs developed in patients with other genetic backgrounds [14]. 
Although these variations are commonly found in benign and metastatic SDHB-
mutated PPGLs, qualitative and/or quantitative deviations could cooperate to set 
the trigger for metastasis development.
Epigenetics is defined as heritable changes in gene expression that do not involve 
a change in DNA sequence. Epigenetic changes occur in many types of cancer cells 
and include DNA methylation, histone modification, and small RNAs. Aberrant 
hypermethylation can lead to silencing of tumor-suppressor genes, histone modi-
fications control the accessibility of the chromatin and transcriptional activities 
inside a cell, and microRNAs (miRNAs) can negatively control their target gene 
expression post-transcriptionally. Herein, we provide a perspective on the recent 
advances and challenges in our understanding of how epigenetic deregulations 
may underlie the progression of SDH-deficient PPGLs towards a metastatic disease 
and highlight promising therapeutic avenues that may be used to counteract those 
epigenetic deregulations.
3.  Succinate: an oncometabolite driving epigenetic deregulation in  
SDH-deficient PPGLs
The SDH complex links the tricarboxylic acid cycle (TCA) and the mitochondria 
respiratory chain by the coupling of succinate oxidation to fumarate to the reduc-
tion of ubiquinone to ubiquinol at the mitochondrial complex II (Figure 1). The 
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fumarate/succinate ratio and the redox state of the ubiquinone pool act as signal 
transducers known to modulate the regulatory programs that control cell fate. Loss 
of SDH activity leads to dramatic elevation of its natural substrate, succinate. The 
succinate generated in the mitochondrial matrix is exported to the cytosol where 
it can inhibit 2-oxoglutarate (2OG)-dependent dioxygenases such as ten-eleven 
translocation (TET) DNA cytosine-oxidizing enzymes and prolyl hydroxylases 
(PHD) [15].
PHD enzymes catalyze the prolyl-hydroxylation of the hypoxia-inducible factors 
HIF1α and HIF2α which transcriptionally regulates HIFα-responsive genes and 
conform the major hub involved in oxygen-sensing (Figure 2). These genes serve to 
adapt cells to oxygen deficiencies and their over-activation under pathologic condi-
tions may also have pro-tumorigenic activity. HIFα proteins are degraded under 
physiological conditions by a mechanism requiring active PHD enzymes. PHD-
catalyzed prolyl-hydroxylation of HIFα proteins is required by their recognition by 
VHL, subsequent ubiquitination and proteasomal degradation. Low oxygen levels 
and succinate repress PHD activities thus leading to the stabilization and functional 
activation of HIFα proteins. This oxygen-sensing pathway has long been considered 
a driver mechanism of metastasis in tumors with SDH-deficiencies [16]. However, 
although HIF1α protein and HIF1α-responsive genes are over-expressed in PPGLs 
carrying SDHx mutations, this signature is much weaker than that of PPGLs car-
rying VHL-loss-of-function mutations which rarely metastasize [17, 18]. Moreover, 
nuclear HIF2α does accumulate in all paragangliomas of the head and neck which 
very scarcely develop metastasis. These observations argue against nuclear HIFα 
Figure 1. 
Schematic representation of the SDH-mediated connection between the Krebs cycle and the mitochondrial 
respiratory chain. The succinate dehydrogenase complex is part of both, the Krebs cycle at the mitochondria 
matrix and the mitochondria respiratory chain in the inner mitochondrial membrane. It is composed of four 
subunits (SDHA, SDHB, SDHC and SDHD) that couples the succinate oxidation to fumarate to the reduction 
of ubiquinone (coenzyme Q: CoQ ) to ubiquinol via FAD at the mitochondrial complex II. The mitochondria 
respiratory chain consists of four membrane-bound, multimeric protein complexes (complexes I, II, III, and 
IV) that catalyzes the oxidation of reducing equivalents, mainly nicotinamide adenine dinucleotide (NADH), 
using the terminal electron acceptor oxygen. This electron transfer is linked to the ATP synthase, which 
generates ATP.
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proteins as the triggers of malignant transformation of SDHx-mutant PPGLs. 
Further research is required to demonstrate whether any, both or none of the HIFα 
proteins are required for malignant transformation of PPGLs.
In addition to PHDs, succinate, which can accumulate to millimolar levels 
in SDHx-mutant PPGLs, is a potent inhibitor of TET enzymes and the Jumonji 
domain-containing histone demethylases [19]. TET enzymes hydroxylate DNA-
methylcytosines into 5-hydroxymethylcytosine leading to DNA demethylation. 
Increased DNA methylation in or near promoter regions, and subsequent decreased 
gene expression, has been associated with oncogenesis in a number of tumor types 
including PPGLs carrying SDHx-mutations [14]. A role for TET enzymes in this 
phenotype has been recently demonstrated [20].
In addition to DNA epigenetic alterations, metastasis in PPGLs patients has also 
been shown to be associated with other epigenetic traits such as aberrant expres-
sion of long non-coding RNA (lncRNA) [21] and microRNAs (miRNAs) [22, 23] 
although these deregulations are not specific of SDH-deficient metastatic PPGLs.
3.1 Succinate-induced DNA hypermethylation
Site-specific DNA hypermethylation in regions of DNA with a high density of 
cytosine-guanine (CpG) dinucleotides in promoters represent a common feature 
of the cancer-associated epigenetic landscape. These CpG hypermethylations are 
linked with repressive chromatin modifications and silencing of tumor suppressor 
Figure 2. 
Oxygen and oncometabolite dependent regulation of HIFα. Under physiological conditions, prolyl hidroxylases 
(PHD) hydroxylate two proline residues in HIFα subunits thus allowing their recognition by the von 
Hipple-Lindau protein (VHL). VHL is a component of a ubiquitination protein complex that ubiquitinate 
(Ub) prolyl-hydroxylated HIFα for degradation by the proteasome. PHDs activity rely on oxygen (O2) and 
oxoglutarate (2-OG). When oxygen concentration diminishes below physiological levels the activity of PHDs is 
inhibited leading to the dissociation of VHL from HIFα which results in HIFα stabilization that is transported 
to the nucleus, binds to HIFβ and activates transcription of target genes by binding to hypoxia-responsive 
elements (HRE) in their promoter regions. Succinate, as well as fumarate, structurally mimics 2-OG and 
inhibits PHDs (product inhibition) when present at elevated concentrations, as observed in tumor cells 
carrying inactivating mutations-driven disfunction of SDH or fumarate hydratase.
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Figure 3. 
Outline of the epigenetic changes induced by abnormal succinate accumulation due to SDHx-mutations. 
Mutations of the SDHx genes in PPGLs cause blockage of SDH activity and subsequent abnormal succinate 
and succinyl-CoA accumulation. Increased levels of succinate induce inhibition of 2-oxoglutarate-dependent 
dioxygenases such as TET enzymes and the Jumonji domain-containing histone demethylases leading 
to activation or repression of gene transcription. TET enzymes hydroxylate DNA-methylcytosines into 
5-hydroxymethylcytosine leading to DNA demethylation. Increased DNA methylation due to impaired TET 
enzyme functions in or near promoter regions induces decreased gene transcription (D) that, when affects 
tumor suppressor genes, such as PCDHGC3, may trigger different aspects of the metastatic programs. Gene 
expression can also be inhibited by succinate-induced inhibition of Jumonji domain-containing histone 
demethylases that remove the methyl group on lysine in histone tails. Histone methylation occurs by the transfer 
of methyl groups from the methyl donor S-adenosylmethionine (SAM) to amino acids of histone proteins. 
This protein modification can either increase or decrease transcription of genes, depending on which amino 
acids are methylated, and how many methyl groups are attached. Succinate inhibition of demethylation of 
trimethylated-H3K27 by the Polycomb complex (PRC2) induce gene silencing and chromatin condensation  
(D). (C) Succinate also represses homology-dependent DNA repair by inhibiting the H3K9 demethylase, 
leading to global elevation of trimethylated H3K9 chromatin marks at loci surrounding DNA breaks. This 
masks a local H3K9 trimethylation signal that is essential for the proper execution of homology-dependent 
DNA repair. (A, B) Apart from repression of gene expression, abnormal succinate accumulation may induce 
gene transcription. This occurs when DNA methylation affects CTCF insulators which prevents CTCF binding 
to CTCF binding sites, CTCF dimerization and the assembly of long-range chromatin looping. This provokes 
promiscuous enhancer-promoter interactions and the subsequent induction of the affected genes (B). (A) 
Increased succinyl-CoA levels induce succinylation of histones associated with enhanced in vitro transcription. 
The figure shows the enzymatic succinylation of histone via the KAT2A histone succinyltransferase which 
associates with α-ketoglutarate dehydrogenase (α-KGDH).
genes. We discuss here the current understanding of the epigenetic basis of metas-
tasis in SDHB-related PPGLs uncovered by our recent studies.
To identify epigenetic alterations relevant for metastasis, we recently performed 
a comprehensive analysis of DNA methylation in metastatic PPGLs with and 
without SDHB mutations. This analysis revealed that over 1000 genes harbored 
promoter hypermethylation in the metastatic tumors but not in the not metastatic 
ones thus suggesting that those gene alterations have a role in the pathogenesis of 
the metastatic disease linked to SDHB mutations [24]. About 15% of these altera-
tions had been also identified in sdhb−/− mouse chromaffin cells and in 41% of 
SDHx-mutated PPGLs analyzed by Letouzé et al. [14]. Although these authors did 
not make distinctions whether the PPGLs were or not metastatic, they did find that 
hypermethylation was stronger in SDHB-PPGLs. Therefore, it is likely that gene 
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mutations in SDHB induce epigenetic programs that may be involved in tumors 
initiation and others involved in metastasis development.
Gene set enrichment analysis revealed that the hypermethylated promoters in 
metastatic SDHB-mutated PPGLs were associated with developmental genes that 
are preferential targets of the polycomb repressive complex 2, PRC2. PRC2 catalyzes 
the mono-methylation, di-methylation and tri-methylation of histone H3 at lysine 
27 required for PRC2-mediated gene silencing and for maintaining cellular identity 
during differentiation and development [25]. Specifically, PRC2 occupies a special 
set of developmental genes in embryonic stem cells that must be repressed to 
maintain pluripotency and that are poised for activation during cell differentiation. 
In cancer, aberrant promoter hypermethylation, or PRC-mediated repression, can 
inhibit differentiation programs, such that cancer cells are arrested at a prolifera-
tive state [26] (see Figure 3). In agreement with these observations, increasingly, 
metabolites, such as succinate, are recognized as important modulators of the 
regulatory programs that control cell fate [27]. Thus, it is tempting to speculate that 
the succinate ‘oncometabolite’ plays an essential role in the epigenetic reprogram-
ing of chromaffin cells such that, when reaching high enough levels, induces the 
transit of mature differentiated cells towards a less differentiated state that allow 
them to proliferate and generate a tumor mass. This could provide an explanation 
for tumorigenesis in SDH-deficient tumors. However, it cannot explain why some 
SDH-deficient PPGLs acquire metastatic fitness, but others do not. The identifica-
tion of an epigenetic signature specific for metastatic SDH-deficient PPGLs, but 
not present in SDH-PPGLs that do not develop metastasis, provides some clues. Our 
recent study revealed that, in addition to the epigenetic changes in developmentally 
regulated genes, high level hypermethylation of genes involved in homophilic cell-
to-cell adhesion was present in metastatic but not in non-metastatic PPGLs SDHB-
mutated PPGLs. Loss of cell–cell adhesion is a hallmark of metastatic cells required 
for the transformation of immobile cells into motile cells providing them the 
ability to invade local tissues leading to metastasis at distant organs. Among these 
hypermethylated genes, we identified CNTN2, SDK1, TENM1, TENM4 encoding 
neuronal cell adhesion molecules involved in the establishment of connections in 
the nervous system. More strikingly, the cell–cell adhesion set of hypermethylated 
genes included a 1 Mb-long chromosomal region that hold clustered protocadherin 
genes [designated as PCDHA, PCDHB and PCDHG (collectively, PCDHs)] encom-
passing 50 different genes at the chromosomal locus 5q31.3 [24] (Figure 4). One of 
the PCDH genes, PCDHGC3, has been further analyzed and found to be of clinical 
relevance in metastatic SDHB-mutated PPGLs.
3.2  Long-range hypermethylation of clustered protocadherin genes in 
metastatic SDHB-mutated PPGLs
PCDH genes, organized into three closely linked gene clusters (PCDHA, 
PCDHB and PCDHG), span nearly 1 million base pairs [28] (Figure 4). The 
PCDHA and PCDHG clusters are organized into variable and constant exons. The 
generation of full-length PCDHA and PCDHG messenger RNA requires RNA 
splicing of each variable exon to three constant exons. Each of the variable exon 
promoters are randomly activated in individual neurons to generate individual 
cell-specific patterns of PCDH gene expression. In contrast, PCDHB mRNA 
consists of only the variable exon. These genes are involved in the regulation of 
neural development and engage in homophilic/heterophilic trans-interactions as 
multimers acting as cell-surface molecular barcodes [29–33]. Their unique genomic 
organization makes them sensitive to long range epigenetic silencing (LRES). 
Several recent studies have revealed that epigenetic silencing of clustered PCDHs is 
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present in various human malignant tumors, such as Wilms tumor, neuroblastoma, 
breast, prostate, colon cancer, gastric and biliary tract cancers, and astrocytoma 
suggesting that this process plays roles in regulating cancer development and/or 
progression [34–37]. By using one of the largest cohorts of epigenetically studied 
SDHB-mutated PPGLs, we have recently found that the epigenetic silencing of one 
of the clustered PCDH genes, PCDHGC3, is putatively involved in the metastatic 
behavior of these tumors [24]. Methylation of PCDHGC3 promoter were found to 
be null in normal paraganglia, null or low in most SDHB-mutated PPGLs that do 
not metastasize, high in SDHB-mutated metastatic PPGLs, and much higher in the 
metastatic tissues derived from these tumors. Similar findings have been reported 
in colorectal cancer, showing that PCDHGC3 is methylated and silenced during the 
adenoma-to-carcinoma transition [37]. These data suggest that this epigenetic trait 
is progressively amplified during the transformation of the tumor cells from benign 
state to the invasive and metastatic states, as suggested for other oncogenes and 
tumor suppressor genes [38].
We also found that, not only PCDHGC3, but the other clustered PCDH genes are 
highly methylated in metastatic SDHx-mutated PPGLs. Indeed, the in-silico analysis 
of DNA methylation data reported by TCGA confirmed the hypermethylation 
of the clustered PCDH genes (Figure 4) in SDHx-mutated PPGLs and allowed 
further analysis of this phenomena. As in our report, methylation of different CpG 
islands were detected in the three clustered PCDHs, being more highly enriched 
in the PCDHG cluster. Figure 4 shows analysis of three different CpG regions in 
that cluster revealing that, similarly to our findings in PCDHGC3 promoter region, 
methylation levels were higher in SDHx-mutated PPGLs than in PPGLs that did 
not harbor SDHx mutations. More importantly, among the SDHB-mutated PPGLs, 
those having a metastatic behavior had a significantly higher levels of methylation 
than tumors that had not developed metastasis at the last follow-up date. Analysis 
of the RNAseq data confirmed the epigenetic silencing of, not only PCDHGC3 [24], 
but also PCDHGC4 gene (Figure 5). The PCDHGC4 mRNA levels were found sig-
nificantly decreased in SDHx-mutated PPGLs as compared with tumors with other 
Figure 4. 
High level long-range hypermethylation of the clustered PCDH genes in metastatic SDHx-mutated PPGLs. 
Schematic representation of the genomic organization of the clustered PCDHA, PCDHB and PCDHG 
genes. For PCDHA and PCDHG genes, only the first exons (blue and orange rectangles, respectively) are 
represented. For PCDHB genes, rectangles represent the whole gene. Inverted gray triangles point to CpG 
hypermethylation sites detected in the SDHx-mutated PPGLs included in the TCGA database. Graphics 
represent DNA methylation levels of the indicated CpG islands (CpGI) according to their genotype. Data 
from patients without or with metastasis are represented in blue and red, respectively. SDHx-WT: PPGLs 
lacking mutations in any of the SDHx genes (include PPGLs with and without mutations in other PPGL-
susceptibility genes); SDHB/D-Mut: Metastatic PPGLs from patients with germline mutations in SDHB 
or SDHD genes; SDHB-Mut: PPGLs from patients with germline mutations in SDHB genes; SDHB-WT: 
Metastatic PPGLs lacking mutations in SDHB genes. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
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genotypes. More importantly, downregulation was significantly more dramatic in 
metastatic than in benign SDHx-mutated tumors. Thus, the corrupted epigenetic 
changes in this chromosomal region seems to amplify the positive selection of the 
most metastatic cells and the evolutionary capacity of cancer to spread out of the 
tissue of origin. Interestingly, only the PCDHGC4 isoform, among the clustered 
PCDH proteins, have been shown to be strictly required for postnatal viability and 
survival of many neuronal subsets [39].
Consistent with previous findings in colon cancer cell lines [37], we found in 
that decreased PCDHGC3 gene expression in two different cancer cell lines resulted 
in significant increases in cell proliferation, cell migration, and collective cell 
invasion. Silencing of PCDHGC3 gene also resulted in increased tumor growth in 
studies of xenograft tumor models in vivo. Consistent with this, the current pub-
lished data showed that PCDHs regulate pathways for cell proliferation and death. 
In tumor tissues derived from PPGLs, loss of PCDH expression is an indicator of 
poor prognosis, as revealed by our data and the in silico analysis of published data. 
Importantly, in SDHB-mutated metastatic PPGLs with high levels of PCDHGC3 
methylation, diagnosis of primary tumor and metastatic disease was synchronous 
in most cases, but some patients had a metastasis-free time ranging from 1 to 
19 years. Thus, it is possible that epigenetic alterations of PCDHGC3 during tumor 
initiation do not automatically lead to the manifestation of full metastatic potential. 
Rather, metastatic potential likely evolves through quantitative amplification, 
ultimately providing the cell with metastatic fitness. Thus, PCDHGC3 acts as a 
tumor suppressor gene in PPGLs, could be an efficient biomarker of malignancy, 
and could represent a novel target for personalized medicine.
Targeting any of the protocadherin genes is challenging given that they are 
highly expressed in nervous system where exert relevant functions for the estab-
lishment and maintenance of specific neuronal connections. It is imperative, thus, 
to unravel the signaling pathways downstream PCDHGC3 to identify potential 
therapeutic targets activated in the absence of PCDHGC3 expression. Current 
published data have shown that PCDHs are tightly linked to several major signal-
ing pathways, including the Wnt/β-catenin and receptor tyrosine kinase signaling 
Figure 5. 
PCDHGC4 gene silencing in SDHB-mutated PPGLs that developed metastasis. PCDHGC4 mRNA levels in 
metastatic (red) and not-metastatic (blue) PPGLs included in the TCGA database are represented according 
to their genotype. SDHx-WT: PPGLs lacking mutations in any of the SDHx genes (include PPGLs with and 
without mutations in other PPGL-susceptibility genes); SDHB/D-Mut: PPGLs from patients with germline 
mutations in SDHB or SDHD genes; SDHB-Mut: Metastatic PPGLs from patients with germline mutations in 
SDHB genes; SDHB-WT: Metastatic PPGLs lacking mutations in SDHB genes. **** P < 0.0001.
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pathways [40–44]. In renal cancer cell lines, we have found that PCDHGC3 loss of 
expression associates with increased mTOR activity. Several reports have shown 
activation of the mTOR pathway in PPGLs [45]. In addition, inhibition of this 
pathway exerts potent antitumor activity in a rat model of pheochromocytoma 
[46]. The epigenetic silencing of PCDHGC3 could, thus, serve as a biomarker for 
the selection of patients appropriate for therapeutic options targeting the mTOR 
pathway.
3.3 Succinate-induced histone methylation
Gene expression can also be altered by changes in chromatin structure via 
chemical modification of amino acids on histone tails. Accumulation of high levels 
of succinate in SDH-deficient PPGLs inhibits JmjC domain-containing histone 
demethylases (KDMs) [19, 47, 48]. These KDMs remove the methyl group on 
lysine in histone tails, which can either activate or repress transcription depending 
on the specifically modified lysine residues. Generally, H3K4, H3K36 and H3K79 
methylations are considered to mark active transcription, whereas H3K9, H3K27 
and H4K20 methylations are thought to be associated with silenced chromatin 
states [49].
Succinate increases methylation of H3K27 and H3K79 [19]. Trimethylation of 
H3K27 is a hallmark of repressed transcription. It is tightly associated with inactive 
gene promoters and also the gene promoters that were found hypermethylated in 
SDHB-mutated metastatic PPGLs. Instead, H3K79 methylation is linked to active 
transcription and may influence transcription elongation and genomic stability 
[50] (Figure 4).
Succinate induces inhibition of the activities of KDM4A which remove methyla-
tion on histone 3 lysine 9 (H3K9) [51, 52]. H3K9 methylation is the mark of hetero-
chromatin, which is the condensed, transcriptionally inactive state of chromatin. 
Importantly, Sulkowski et al. have recently shown that increased succinate levels, 
induced by SDH silencing, can also repress homology-dependent DNA repair 
(HDR) by directly inhibiting the H3K9 demethylase KDM4B, leading to global 
elevation of trimethylated H3K9 chromatin marks at loci surrounding DNA breaks. 
This masks a local H3K9 trimethylation signal that is essential for the proper execu-
tion of HDR [51] (Figure 4). This finding underscores the notion that decreased 
DNA repair acts as a key oncogenic mechanism in SDH-deficient PPGLs, similarly 
to the underlying mechanisms of the familial breast and ovarian cancer predisposi-
tion syndromes linked to the BRCA1 and BRCA2 genes.
3.4 Succinate-induced loss of insulators
DNA hypermethylation outside of gene promoters may also have significant 
impacts on PPGL pathophysiology, especially when hypermethylation occurs at 
the CCCTC-binding factor (CTCF) insulators. Insulators are DNA regulatory 
elements that block the interaction between gene enhancers and gene promot-
ers. They block the spreading of enhancers action and thus insulate, or shield, 
gene promoters from unwanted regulation [53, 54]. CTCF dimerization, when 
it is bound to different DNA sequences, mediates long-range chromatin loop-
ing allowing the insulation of promoters from enhancer sequences (Figure 4). 
Many proto-oncogenes are isolated in such domains and thus protected from 
promiscuous enhancer interactions. The CTCF insulator is methylation-sensitive 
and may be displaced by DNA methylation. DNA hypermethylation at CTCF 
insulators is traduced in promiscuous enhancer-promoter interactions with the 
subsequent induction of the affected genes [53, 55].
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Recent studies of SDH-deficient gastrointestinal stromal tumors (GISTs) 
have uncovered the frequent hypermethylation of CTCF insulators where DNA 
methylation replaces CTCF binding [55, 56]. This ubiquitous insulator losses leads 
SDH-deficient cells to acquire promiscuous enhancer-promoter interactions and 
an altered genome topology promoting expression of genes such as FGF4 or KIT 
involved in the oncogenic programs activated in GIST. This discovery raises the 
interesting possibility that SDH-deficiency in PPGLs may drive oncogenic pro-
grams, in the absence of DNA mutations, by epigenetic modifications that alter 
genome topology and the enhancer/promoter functions.
3.5 Succinate-induced protein succinylation
SDH inactivation induces accumulation of the immediate upstream metabolite, 
succinyl-CoA. Succinyl-CoA is the substrate used for the succinylation of proteins, 
in which succinyl group is transferred to a lysine residue of a protein. It is a recently 
identified common and widespread posttranslational modification that directly 
couples TCA cycle metabolism, via succinyl-CoA, to alterations in the structures 
and activities of proteins involved in diverse cellular processes [57].
Lysine succinylation can occur by a non-enzymatic chemical reaction. This 
suggests that the abundance of succinyl-CoA would be one of the main governing 
factors of protein succinylation. A recent study have demonstrated that knockdown 
of SDHB leads to global lysine hyper-succinylation in multiple cellular compart-
ments, especially mitochondria, coupled with increased succinyl-CoA levels [58]. 
Succinate-induced hypersuccinylation results in apoptosis resistance suggesting a 
relevant role in tumorigenesis and metastasis development. Succinylation can also 
occur at the nuclei. In this regard, Wang et al. have demonstrated that the lysine 
acetyltransferase 2A (KAT2A) may also act as a histone succinyltransferase by 
forming a complex with α-ketoglutarate dehydrogenase (α-KGDH) that catalyzes 
the conversion of α-ketoglutarate (α-KG) to succinyl-CoA in the promoter regions 
of genes [59] (Figure 4). Indeed, more than one-third of nucleosomes, including 
histone and non-histone chromatin components, have been shown to be lysine 
succinylated in the absence of functional SDH activity suggesting that SDH loss 
has significant effects on chromatin structure and function and subsequent gene 
expression [60]. These succinyl marks in chromatin coincide with H3K4me3-
chromatin marks, but not with H3K27me3-chromatin marks, suggesting that 
succinylation of chromatin at active gene promoters is functionally meaningful. 
Histone succinylation induces widespread gene expression changes that promote 
tumor growth [61, 62]. However, how histone and nonhistone protein succinylation 
affects tumorigenesis remains largely unexplored and deserve in-depth character-
ization to unravel their putative involvement in metastasis development in patients 
with SDHB-mutations and to develop drug therapies and targeted agents.
4. microRNA and lncRNA
RNA-based mechanisms of epigenetic regulation are less well understood than 
mechanisms involved on DNA methylation and histones but have also profound 
roles in gene regulation, development and tumorigenesis. Several recent studies 
have analyzed the pattern of expression of non-coding RNAs, including microRNAs 
(miRNAs) and long-non-coding RNAs (lncRNAs), in metastatic PPGLs.
Mature miRNAs (~22 nucleotides long) base-pair with target mRNAs to inhibit 
translation or direct mRNA degradation. Several studies have shown over-expression 
of miR-183 in metastatic compared with non-metastatic PPGLs, irrespective of 
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the genotype of the tumor [23, 63]. Higher levels of miR-483-5p have been also in 
metastatic tumors compared with benign tumors [23, 64]. Given the rarity of PPGLs, 
in general, and of metastatic PPGLs with SDHB mutations, in particular, the putative 
involvement of SDH-deficiency mediated miRNA deregulation in metastasis devel-
opment is yet unknown.
miR-210 is one of the best characterized miRNAs downstream HIF1α activa-
tion and a candidate tumor-driver of metabolic reprogramming in cancer [65]. 
Some studies have proposed that up-regulation of miR-210 is a hallmark of the 
VHL/SDHx-mutated PPGLs [66] whereas others have ascribed it a role exclusively 
in VHL-mutated tumors [18]. One of the targets of miR-210 is the gene that codi-
fies the iron–sulfur cluster assembly enzyme (ISCU) required for the assembly 
of maturation of Fe-S clusters, critical bioinorganic prosthetic groups essential 
for electron transport and multiple metabolic processes [67]. The miR-210-ISCU 
signaling pathway, a hallmark of the HIF activation in cancer, is activated in SDHx 
and VHL-mutated PPGLs [18]. However, the role of miR-210 in metastasis predis-
position of SDHB-mutated PPGLs is not known. A recent report showed that the 
serum levels of miR-210 are decreased in metastatic PPGLs [68] although these data 
were grounded in a very limited number of samples and has not been confirmed 
in publicly available databases. For example, in silico analysis of the TCGA data-
base confirms previous reports showing that miR-210 is highly over-expressed in 
VHL-mutated PPGLs and moderately up-regulated in SDHB-PPGLs although this 
was independent on whether the tumor had or not metastatic behavior (Figure 6). 
Similarly, ISCU mRNA levels more dramatically decreased in VHL-mutated than 
in SDHx-mutated PPGLs. Among SDHB-mutated PPGLs, the differences of ISCU 
levels were not significant enough to assign it a role as biomarker of metastasis 
development. miR-210 was not found over-expressed, neither was ISCU under-
expressed, in tumors carrying somatic mutations of the gene encoding the HIF2α 
subunit (EPAS1) of the HIF transcription factor thus confirming previous reports 
showing that this miRNA is a substrate of HIF1α but not HIF2α [69], at least, in the 
context of paraganglionar tissues. Thus, the available data suggest that miR-210 
should not be used as a biomarker of metastatic SDHB-mutated PPGLs.
Figure 6. 
miR-210-ISCU signaling is moderately activated in SDHx-mutated PPGLs irrespective of their benign or 
metastatic behavior. miR-210-3p and ISCU levels in PPGLs included in the TCGA database are represented 
according to their genotype. Data from patients without or with metastasis are represented in blue and red, 
respectively. SDHB/D: PPGLs from patients with germline mutations in SDHB or SDHD genes; VHL: PPGLs 
with mutations in VHL; EPAS1: PPGLs with mutations in EPAS1; others: PPGLs with or without mutations 
in other PPGL-susceptibility genes; SDHB: metastatic PPGLs from patients with germline mutations in SDHB 
gene; **** P < 0.0001.
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lncRNAs are usually defined as non-coding RNAs greater than 200 nucleotides 
[70]. Although their functions are not well understood they seem to have key roles 
in gene regulation which depend on their localization and their specific interactions 
with DNA, RNA and proteins. Their tissue-specific and condition-specific expres-
sion patterns suggest that lncRNAs could be potential biomarkers. Recent reports 
described DGCR9, FENDRR, HIF1A-AS2, MIR210HG [71] and BC063866 [21] 
with significantly elevated expression in metastatic compared to benign PPGLs. 
Expression of BC063866 was found significantly elevated in SDHx-mutated meta-
static PPGLs and, if validated in larger series, could be a novel biomarker to identify 
potentially metastatic tumors in patients carrying SDHB mutation.
5.  Epigenetic drugs as therapeutic strategies for patients with metastatic 
PPGLs
Among epigenetic drugs, despite their limitations, DNA methyltransferase 
(DNMT) inhibitors are the most effective epigenetic therapy developed to date. 
Azacitidine and decitabine are cytidine analogues that incorporate themselves 
into replicating DNA and inhibit DNMTs. This implies that these inhibitors have 
broad cellular effects leading to global loss of DNA methylation. Hence their use as 
epigenetic drugs have to deal with strategies to minimize the off-target effects. The 
use of effective methods for drug delivery reduces side effects and attains a higher 
therapeutic index. There are various delivery systems like nanocarriers (nanogels, 
liposomes, dendrimers, and polymeric nanoparticles) that enhance drug stability, 
permeability and retention. Low doses have received regulatory approval for the 
treatment of myelodysplastic syndrome and acute myeloid leukemia who are not 
candidates for conventional induction chemotherapy. The use of the DNMT inhibi-
tor, guadecitabine, is currently been evaluated in patients with PPGLs associated 
with SDH-deficiency under phase II clinical trial.
Other epigenetic drugs include the inhibitors of histone-lysine methyltransfer-
ases [72]. Multiple PRC2 inhibitors are currently being evaluated in ongoing phase 
I/II clinical trials in a range of cancers [73]. Most hypermethylated genes in meta-
static SDHB-mutated PPGLs are PRC2 targets thus suggesting that patients could be 
benefited by the use of these epigenetic drugs [24].
The findings that overproduction of succinate suppresses HDR provide a mecha-
nistic basis for the use novel effective strategies to exploit these defects for thera-
peutic gain. HDR repression in SDH-deficient tumors enhances cellular dependence 
on alternative, poly [ADP-ribose] polymerase (PARP) dependent DNA repair 
mechanisms, which appears to offer a compelling opportunity for targeted thera-
peutic intervention in oncometabolite-driven cancers. A large body of scientific 
evidence and clinical trials led to FDA approval of PARP inhibitor monotherapy for 
the treatment of various cancers harboring mutations in HDR machinery, including 
those with BRCA1/2 loss [74]. It should be explored whether the HDR defect con-
ferred by succinate accumulation is strong enough to put into practice this thera-
peutic strategy in SDH-deficient driven cancers. One interesting possibility will 
be to add DNA-damaging therapies to PARP antagonists to maximize therapeutic 
efficacy. Notably, the PARP inhibitor olaparib in combination with temozolamide is 
currently undergoing testing in phase II clinical study in metastatic PPGLs.
Hypersuccinylation can also be a target of therapy in metastatic PPGLs. 
Succinyl-CoA accumulated in SDH-deficient tumors can be condensed with glycine 
by D-aminolevulinate synthase 1 to form 5-aminolevulinate and enter the heme 
biosynthesis pathway. Therefore, glycine supplementation may facilitate removal 
of succinyl-CoA and inhibit succinylation. Relief of hypersuccinylation by glycine 
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supplementation, has been shown to result in inhibited growth of hypersuccinylated 
tumors [59], thus shedding lights on alternative approaches for SDHx-mutated-PPGLs.
6. Conclusions
Metastasis is the most letal attribute of PPGLs, especially in patients with 
compromised SDH activity. Since the initial discovery of succinate as an oncome-
tabolite that induces DNA hypermethylation, the knowledges that illustrate its role 
on epigenetic reprogramming and metastasis development continues to expand. 
The best characterized changes, DNA and histone methylation, could be efficiently 
and globally neutralized by DNA or histone hypomethylating agents, well-known 
epi-drugs that could be tested as single- or multi-drug therapy in metastatic SDH-
deficient PPGLs. The activity of these epigenetic therapies, however, is not limited 
to cancer cells but have broad cellular effects leading to global loss of DNA methyla-
tion and off-target effects. Emerging scientific knowledges on the impacts that 
succinate-induced modification of the epigenetic code has on cancer development 
and progression is certainly empowering the research community to develop more 
effective, less toxic, and better tolerated therapies.
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